ALTEOGEN Inc. (196170.KQ)
KRW 286500.0
(-3.54%)
KRW 286500.0
(-3.54%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -3.37 Billion KRW | 58.61% |
| 2022 | -8.14 Billion KRW | -29.82% |
| 2021 | -6.27 Billion KRW | 60.34% |
| 2020 | -15.82 Billion KRW | -2145.77% |
| 2019 | -704.51 Million KRW | 89.75% |
| 2018 | -6.87 Billion KRW | 7.74% |
| 2017 | -7.44 Billion KRW | -107.65% |
| 2016 | -3.58 Billion KRW | -396.86% |
| 2015 | 1.2 Billion KRW | 29.77% |
| 2014 | 931.14 Million KRW | -42.02% |
| 2013 | 1.6 Billion KRW | 12.01% |
| 2012 | 1.43 Billion KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -2.91 Billion KRW | -113.92% |
| 2024 Q1 | 20.96 Billion KRW | 279.78% |
| 2023 FY | -3.37 Billion KRW | 58.61% |
| 2023 Q3 | -7.66 Billion KRW | -132.07% |
| 2023 Q4 | -11.66 Billion KRW | -52.11% |
| 2023 Q2 | 23.9 Billion KRW | 400.79% |
| 2023 Q1 | -7.94 Billion KRW | -263.18% |
| 2022 FY | -8.14 Billion KRW | -29.82% |
| 2022 Q4 | -2.18 Billion KRW | 64.43% |
| 2022 Q3 | -6.15 Billion KRW | -8.96% |
| 2022 Q2 | -5.64 Billion KRW | -196.69% |
| 2022 Q1 | 5.83 Billion KRW | -43.44% |
| 2021 Q3 | -8.25 Billion KRW | -21.69% |
| 2021 Q4 | 10.32 Billion KRW | 225.05% |
| 2021 Q1 | 837.47 Million KRW | 103.35% |
| 2021 FY | -6.27 Billion KRW | 60.34% |
| 2021 Q2 | -6.78 Billion KRW | -910.03% |
| 2020 Q2 | 2.44 Billion KRW | -5.81% |
| 2020 Q4 | -25.01 Billion KRW | -703.95% |
| 2020 Q3 | 4.14 Billion KRW | 69.14% |
| 2020 FY | -15.82 Billion KRW | -2145.77% |
| 2020 Q1 | 2.59 Billion KRW | -58.3% |
| 2019 Q3 | -2.24 Billion KRW | -41.0% |
| 2019 Q1 | -3.1 Billion KRW | -223.07% |
| 2019 FY | -704.51 Million KRW | 89.75% |
| 2019 Q4 | 6.23 Billion KRW | 377.99% |
| 2019 Q2 | -1.59 Billion KRW | 48.78% |
| 2018 FY | -6.87 Billion KRW | 7.74% |
| 2018 Q4 | -961.3 Million KRW | 67.04% |
| 2018 Q3 | -2.91 Billion KRW | -166.6% |
| 2018 Q2 | -1.09 Billion KRW | 42.42% |
| 2018 Q1 | -1.9 Billion KRW | 67.6% |
| 2017 Q2 | -1.48 Billion KRW | -250.67% |
| 2017 FY | -7.44 Billion KRW | -107.65% |
| 2017 Q4 | -5.86 Billion KRW | -439.82% |
| 2017 Q1 | 982.49 Million KRW | 178.4% |
| 2017 Q3 | -1.08 Billion KRW | 26.61% |
| 2016 Q2 | -569.98 Million KRW | 11.52% |
| 2016 Q4 | -1.25 Billion KRW | -11.9% |
| 2016 FY | -3.58 Billion KRW | -396.86% |
| 2016 Q1 | -644.19 Million KRW | -175.52% |
| 2016 Q3 | -1.11 Billion KRW | -96.47% |
| 2015 Q2 | -504.54 Million KRW | -172.11% |
| 2015 Q1 | 699.74 Million KRW | 3982.53% |
| 2015 FY | 1.2 Billion KRW | 29.77% |
| 2015 Q4 | 853 Million KRW | 432.56% |
| 2015 Q3 | 160.17 Million KRW | 131.75% |
| 2014 Q4 | -18.02 Million KRW | -112.6% |
| 2014 FY | 931.14 Million KRW | -42.02% |
| 2014 Q1 | 421.93 Million KRW | 102.05% |
| 2014 Q2 | 384.14 Million KRW | -8.95% |
| 2014 Q3 | 143.08 Million KRW | -62.75% |
| 2013 FY | 1.6 Billion KRW | 12.01% |
| 2013 Q1 | 594.18 Million KRW | 0.0% |
| 2013 Q2 | 594.18 Million KRW | 0.0% |
| 2013 Q4 | 208.82 Million KRW | 0.0% |
| 2013 Q3 | 208.82 Million KRW | -64.86% |
| 2012 FY | 1.43 Billion KRW | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| HLB Co., Ltd. | -189.07 Billion KRW | 98.217% |
| iNtRON Biotechnology, Inc. | -9.69 Billion KRW | 65.223% |
| BINEX Co., Ltd. | 4.67 Billion KRW | 172.189% |
| Bioneer Corporation | -10.58 Billion KRW | 68.152% |
| Anterogen.Co.,Ltd. | -2.84 Billion KRW | -18.689% |
| MEDIPOST Co., Ltd. | 5.83 Billion KRW | 157.736% |
| CrystalGenomics, Inc. | -48.92 Billion KRW | 93.108% |
| Helixmith Co., Ltd | -64.08 Billion KRW | 94.739% |
| Chabiotech Co.,Ltd. | -8.43 Billion KRW | 60.009% |
| Medy-Tox Inc. | 9.75 Billion KRW | 134.564% |
| Peptron, Inc. | -15.92 Billion KRW | 78.823% |
| Amicogen, Inc. | -23.28 Billion KRW | 85.522% |
| Genexine, Inc. | -66.87 Billion KRW | 94.958% |
| HLB Therapeutics Co.,Ltd. | -2.3 Billion KRW | -46.461% |
| LegoChem Biosciences, Inc. | -73.7 Billion KRW | 95.425% |
| PharmaResearch Co., Ltd. | 76.55 Billion KRW | 104.405% |
| SillaJen, Inc. | -20.36 Billion KRW | 83.447% |
| JETEMA, Co., Ltd. | 13.96 Billion KRW | 124.143% |
| OliX Pharmaceuticals,Inc | -19.1 Billion KRW | 82.348% |
| Genomictree Inc. | -8.75 Billion KRW | 61.492% |
| MedPacto, Inc. | -35.32 Billion KRW | 90.455% |
| D&D Pharmatech | 3.93 Billion KRW | 185.713% |
| EASY BIO,Inc. | 15.54 Billion KRW | 121.692% |
| GI Innovation, Inc. | -55.49 Billion KRW | 93.924% |